Edition:
United Kingdom

Mirati Therapeutics Inc (MRTX.OQ)

MRTX.OQ on NASDAQ Stock Exchange Capital Market

17.30USD
14 Dec 2017
Change (% chg)

$0.40 (+2.37%)
Prev Close
$16.90
Open
$17.05
Day's High
$17.65
Day's Low
$16.70
Volume
85,808
Avg. Vol
176,639
52-wk High
$19.10
52-wk Low
$2.70

Chart for

About

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $362.06
Shares Outstanding(Mil.): 24.97
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Mirati announces advancement of opportunities with inhibitor programs

* Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs

13 Nov 2017

BRIEF-Mirati Therapeutics reports Q3 loss per share of $0.65

* Mirati Therapeutics reports third quarter 2017 financial results

01 Nov 2017

BRIEF-Mirati Therapeutics' says drug included in Stand Up To Cancer's clinical trial initiative for NSCLC patients

* Mirati Therapeutics' mocetinostat included in stand up to cancer's cutting-edge clinical trial initiative for NSCLC patients Source text for Eikon: Further company coverage:

12 Oct 2017

BRIEF-Mirati Therapeutics presents positive data from on-going clinical trials of sitravatinib

* Mirati Therapeutics Inc presents positive preliminary data from on-going clinical trials of sitravatinib in non-small cell lung cancer

14 Sep 2017

BRIEF-Mirati Therapeutics reports Q2 loss per share $0.74

* Mirati Therapeutics reports second quarter 2017 financial results

03 Aug 2017

Earnings vs. Estimates